Andrew Worden - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Andrew Worden

Showing results (11-20 of 13) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 13 results.

Frontiers in Immunology|August 28, 2020

Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of Non-hodgkin LymphomaZachary Jackson, Anne Roe, Ashish Arunkumar Sharma, et al.

Nature Communications|December 11, 2021

Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patientsMichael Maschan, Paolo F Caimi, Jane Reese-Koc, et al.

Eclinicalmedicine|March 21, 2025

Treatment of non-Hodgkin lymphoma with point-of-care manufactured CAR T cells: a dual institution, phase 1 trialArmin Ghobadi, Paolo F Caimi, Jane S Reese, et al.

Pageof 2

Search research articles

Showing results (11-20 of 13) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 13 results.

Frontiers in Immunology|August 28, 2020

Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of Non-hodgkin LymphomaZachary Jackson, Anne Roe, Ashish Arunkumar Sharma, et al.

Nature Communications|December 11, 2021

Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patientsMichael Maschan, Paolo F Caimi, Jane Reese-Koc, et al.

Eclinicalmedicine|March 21, 2025

Treatment of non-Hodgkin lymphoma with point-of-care manufactured CAR T cells: a dual institution, phase 1 trialArmin Ghobadi, Paolo F Caimi, Jane S Reese, et al.

Pageof 2